Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GLA | P06280 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | CASP7 | P55210 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23723247 | 0.89 | APP (0.42) | APPPDE5AMAOAMAOBKDM4E | |
| SCHEMBL7330670 | 0.83 | APP (0.40) | APPPDE5AMAOAMAOBKDM4E | |
| SCHEMBL31416041 | 0.79 | CACNA2D1 (0.40) | APPPDE5AKDM4EALDH1A1GBA1 | |
| SCHEMBL3113119 | 0.78 | MAOA (0.42) | APPPDE5AMAOAMAOBKDM4E | |
| SCHEMBL8901339 | 0.76 | GBA1 (0.40) | APPPDE5AMAOAMAOBKDM4E | |
| SCHEMBL4031318 | 0.75 | KDM4E (0.49) | APPPDE5AMAOAMAOBKDM4E | |
| SCHEMBL3113231 | 0.75 | APP (0.41) | APPKMT2AHTTMAPTLMNA | |
| SCHEMBL3113186 | 0.75 | EGFR (0.49) | APPKMT2ALMNAEGFRPDGFRB | |
| SCHEMBL8890674 | 0.74 | MAOA (0.39) | APPPDE5AMAOAMAOBKDM4E | |
| SCHEMBL3106594 | 0.74 | MAPT (0.42) | APPPDE5AMAOAMAOBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| EP-4100395-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021155426-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | NQO2, TP53, ABL1 | APP 4864/4885PDE5A 784/4885MAOA 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.